Activation and regulation of caspase-6 and its role in neurodegenerative diseases

Annual Review of Pharmacology and Toxicology

Volumn 55, Issue , 2015, Pages 553-572

  Wang, Xiao Jun ^a   Cao, Qin ^a   Zhang, Yan ^a   Su, Xiao Dong ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Caspase 6; Huntington's disease; Neurodegeneration; Regulation mechanism

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CASPASE 6; CASPASE 6 INHIBITOR; CASPASE INHIBITOR; HUNTINGTIN; UNCLASSIFIED DRUG; HTT PROTEIN, HUMAN; NERVE PROTEIN;

ALZHEIMER DISEASE; BRAIN DYSFUNCTION; DEGENERATIVE DISEASE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SPECIFICITY; ENZYME STRUCTURE; GENE CONTROL; HUMAN; HUNTINGTON CHOREA; NERVE CELL; NERVE FIBER DEGENERATION; NEUROMODULATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; AMINO ACID SEQUENCE; ANIMAL; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; HUNTINGTON DISEASE; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CASPASE 6; CASPASE INHIBITORS; DRUG DESIGN; ENZYME ACTIVATION; HUMANS; HUNTINGTON DISEASE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 84920836462     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010814-124414     Document Type: Review

References (133)

1. Riedl SJ, Shi Y. 2004. Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev. Mol. Cell Biol. 5:897-907
2. Yan N, Shi Y. 2005. Mechanisms of apoptosis through structural biology. Annu. Rev. Cell Dev. Biol. 21:35-56
3. Fuentes-Prior P, Salvesen GS. 2004. The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem. J. 384:201-32
4. Fernandes-Alnemri T, Litwack G, Alnemri ES. 1995. Mch2, a new member of the apoptotic Ced-3/Ice cysteine protease gene family. Cancer Res. 55:2737-42
5. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, et al. 1999. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J. Cell Biol. 144:281-92
6. Hirata H, Takahashi A, Kobayashi S, Yonehara S, Sawai H, et al. 1998. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J. Exp. Med. 187:587-600
7. Allsopp TE, McLuckie J, Kerr LE, Macleod M, Sharkey J, Kelly JS. 2000. Caspase 6 activity initiates caspase 3 activation in cerebellar granule cell apoptosis. Cell Death Differ. 7:984-93
8. Doostzadeh-Cizeron J, Yin S, Goodrich DW. 2000. Apoptosis induced by the nuclear death domain protein p84N5 is associated with caspase-6 and NF-βB activation. J. Biol. Chem. 275:25336-41
9. LeBlanc A, Liu H, Goodyer C, Bergeron C, Hammond J. 1999. Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimers disease. J. Biol. Chem. 274:23426-36
10. Klaiman G, Champagne N, LeBlanc AC. 2009. Self-activation ofCaspase-6 in vitro and in vivo:Caspase- 6 activation does not induce cell death in HEK293T cells. Biochim. Biophys. Acta 1793:592-601
11. Wang XJ, Cao Q, Liu X, Wang KT, Mi W, et al. 2010. Crystal structures of human caspase 6 reveal a new mechanism for intramolecular cleavage self-activation. EMBO Rep. 11:841-47
12. Orth K, Chinnaiyan AM, Garg M, Froelich CJ, Dixit VM. 1996. The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J. Biol. Chem. 271:16443-46
13. Levkau B, Scatena M, Giachelli CM, Ross R, Raines EW. 1999. Apoptosis overrides survival signals through a caspase-mediated dominant-negative NF-βB loop. Nat. Cell Biol. 1:227-33
14. Galande S, Dickinson LA, Mian IS, Sikorska M, Kohwi-Shigematsu T. 2001. SATB1 cleavage by caspase 6 disrupts PDZ domain-mediated dimerization, causing detachment from chromatin early in T-cell apoptosis. Mol. Cell. Biol. 21:5591-604
15. Nyormoi O, Wang Z, Doan D, Ruiz M, McConkey D, Bar-Eli M. 2001. Transcription factor AP-2α is preferentially cleaved by caspase 6 and degraded by proteasome during tumor necrosis factor α-induced apoptosis in breast cancer cells. Mol. Cell. Biol. 21:4856-67
16. Rouaux C, Jokic N, Mbebi C, Boutillier S, Loeffler JP, Boutillier AL. 2003. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J. 22:6537-49
17. Guo H, Albrecht S, Bourdeau M, Petzke T, Bergeron C, LeBlanc AC. 2004. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimers disease. Am. J. Pathol. 165:523-31
18. Albrecht S, Bourdeau M, Bennett D, Mufson EJ, Bhattacharjee M, LeBlanc AC. 2007. Activation of caspase-6 in aging and mild cognitive impairment. Am. J. Pathol. 170:1200-9
19. Graham RK, Deng Y, Carroll J, Vaid K, Cowan C, et al. 2010. Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. J. Neurosci. 30:15019-29
20. Singh AB, Kaushal V, Megyesi JK, Shah SV, Kaushal GP. 2002. Cloning and expression of rat caspase-6 and its localization in renal ischemia/reperfusion injury. Kidney Int. 62:106-15
21. Godefroy N, Foveau B, Albrecht S, Goodyer CG, LeBlanc AC. 2013. Expression and activation of caspase-6 in human fetal and adult tissues. PLoS ONE 8:e79313
22. Nikolaev A, McLaughlin T, OLeary DD, Tessier-Lavigne M. 2009. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457:981-89
23. Schoenmann Z, Assa-Kunik E, Tiomny S, Minis A, Haklai-Topper L, et al. 2010. Axonal degeneration is regulated by the apoptotic machinery or a NAD+-sensitive pathway in insects and mammals. J. Neurosci. 30:6375-86
24. Harrington EP, Zhao C, Fancy SP, Kaing S, Franklin RJ, Rowitch DH. 2010. Oligodendrocyte PTEN is required for myelin and axonal integrity, not remyelination. Ann. Neurol. 68:703-16
25. Simon DJ, Weimer RM, McLaughlin T, Kallop D, Stanger K, et al. 2012. A caspase cascade regulating developmental axon degeneration. J. Neurosci. 32:17540-53
26. Park KJ, Grosso CA, Aubert I, Kaplan DR, Miller FD. 2010. p75NTR-dependent, myelin-mediated axonal degeneration regulates neural connectivity in the adult brain. Nat. Neurosci. 13:559-66
27. Vohra BP, Sasaki Y, Miller BR, Chang J, DiAntonio A, Milbrandt J. 2010. Amyloid precursor protein cleavage-dependent and -independent axonal degeneration programs share a common nicotinamide mononucleotide adenylyltransferase 1-sensitive pathway. J. Neurosci. 30:13729-38
28. Akpan N, Serrano-Saiz E, Zacharia BE, Otten ML, Ducruet AF, et al. 2011. Intranasal delivery of caspase-9 inhibitor reduces caspase-6-dependent axon/neuron loss and improves neurological function after stroke. J. Neurosci. 31:8894-904
29. Uribe V, Wong BK, Graham RK, Cusack CL, Skotte NH, et al. 2012. Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice. Hum. Mol. Genet. 21:1954-67
30. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, et al. 2006. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125:1179-91
31. Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, et al. 2004. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntingtons disease. Cell Death Differ. 11:424-38
32. Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, et al. 2009. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 132:919-32
33. Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, et al. 2010. Early increase in extrasynapticNMDA receptor signaling and expression contributes to phenotype onset in Huntingtons disease mice. Neuron 65:178-90
34. Warby SC, Doty CN, Graham RK, Carroll JB, Yang YZ, et al. 2008. Activated caspase-6 and caspase- 6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Hum. Mol. Genet. 17:2390-404
35. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, et al. 1999. Involvement of caspases in proteolytic cleavage of Alzheimers amyloid-β precursor protein and amyloidogenic Aβ peptide formation. Cell 97:395-406
36. Galvan V, Chen S, Lu D, Logvinova A, Goldsmith P, et al. 2002. Caspase cleavage of members of the amyloid precursor family of proteins. J. Neurochem. 82:283-94
37. Lu DC, Rabizadeh S, Chandra S, Shayya RF, Ellerby LM, et al. 2000. A second cytotoxic proteolytic peptide derived from amyloid β-protein precursor. Nat. Med. 6:397-404
38. Zhao M, Su J, Head E, Cotman CW. 2003. Accumulation of caspase cleaved amyloid precursor protein represents an early neurodegenerative event in aging and in Alzheimers disease. Neurobiol. Dis. 14:391-403
39. Saganich MJ, Schroeder BE, Galvan V, Bredesen DE, Koo EH, Heinemann SF. 2006. Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP. J. Neurosci. 26:13428-36
40. Nguyen TV, Galvan V, Huang W, Banwait S, Tang H, et al. 2008. Signal transduction in Alzheimer disease: p21-activated kinase signaling requires C-terminal cleavage of APP at Asp664. J. Neurochem. 104:1065-80
41. Galvan V, Gorostiza OF, Banwait S, Ataie M, Logvinova AV, et al. 2006. Reversal of Alzheimers-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc. Natl. Acad. Sci. USA 103:7130-35
42. Cao Q, Wang XJ, Liu CW, Liu DF, Li LF, et al. 2012. Inhibitory mechanism of caspase-6 phosphorylation revealed by crystal structures, molecular dynamics simulations, and biochemical assays. J. Biol. Chem. 287:15371-79
43. Velazquez-Delgado EM, Hardy JA. 2012. Phosphorylation regulates assembly of the caspase-6 substratebinding groove. Structure 20:742-51
44. Cao Q, Wang XJ, Li LF, Su XD. 2014. The regulatory mechanism of the caspase 6 pro-domain revealed by crystal structure and biochemical assays. Acta Crystallogr. D Biol. Crystallogr. 70:58-67
45. Novak MJ, Tabrizi SJ. 2010. Huntingtons disease. BMJ 340:c3109
46. TheHuntingtons Disease Collaborative Research Group. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntingtons disease chromosomes. Cell 72:971-83
47. Strong TV, Tagle DA, Valdes JM, Elmer LW, Boehm K, et al. 1993. Widespread expression of the human and rat Huntingtons disease gene in brain and nonneural tissues. Nat. Genet. 5:259-65
48. De Rooij KE, Dorsman JC, Smoor MA, Den Dunnen JT, VanOmmen GJ. 1996. Subcellular localization of theHuntingtons disease gene product in cell lines by immunofluorescence and biochemical subcellular fractionation. Hum. Mol. Genet. 5:1093-99
49. DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, et al. 1995. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14:1075-81
50. Saudou F, Devys D, Trottier Y, Imbert G, Stoeckel ME, et al. 1996. Polyglutamine expansions and neurodegenerative diseases. Cold Spring Harb. Symp. Quant. Biol. 61:639-47
51. Harjes P, Wanker EE. 2003. The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem. Sci. 28:425-33
52. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, et al. 2001. Loss of huntingtin-mediated BDNF gene transcription in Huntingtons disease. Science 293:493-98
53. Ehrnhoefer DE, Sutton L, Hayden MR. 2011. Small changes, big impact: posttranslationalmodifications and function of huntingtin in Huntington disease. Neuroscientist 17:475-92
54. Menalled LB, Chesselet MF. 2002. Mousemodels of Huntingtons disease. Trends Pharmacol. Sci. 23:32-39
55. Crook ZR, Housman D. 2011. Huntingtons disease: Can mice lead the way to treatment? Neuron 69:423-35
56. Graham RK, Slow EJ, Deng Y, Bissada N, Lu G, et al. 2006. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiol. Dis. 21:444-55
57. Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, et al. 2000. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J. Biol. Chem. 275:19831-38
58. Wellington CL, Ellerby LM, Hackam AS, Margolis RL, Trifiro MA, et al. 1998. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 273:9158-67
59. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, et al. 1996. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493-506
60. Hackam AS, Singaraja R, Wellington CL, Metzler M, McCutcheon K, et al. 1998. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J. Cell Biol. 141:1097-105
61. Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, et al. 2002. Caspase cleavage ofmutant huntingtin precedes neurodegeneration in Huntingtons disease. J. Neurosci. 22:7862-72
62. Gafni J, Papanikolaou T, Degiacomo F, Holcomb J, Chen S, et al. 2012. Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment. J. Neurosci. 32:7454-65
63. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, et al. 1997. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537-48
64. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, et al. 1999. Nuclear and neuropil aggregates in Huntingtons disease: relationship to neuropathology. J. Neurosci. 19:2522-34
65. Van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR. 2005. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 14:3823-35
66. Saudou F, Finkbeiner S, Devys D, Greenberg ME. 1998. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55-66
67. Kim M, Lee HS, LaForet G, McIntyre C, Martin EJ, et al. 1999. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J. Neurosci. 19:964-73
68. Lerch JP, Carroll JB, Spring S, Bertram LN, Schwab C, et al. 2008. Automated deformation analysis in the YAC128 Huntington disease mouse model. NeuroImage 39:32-39
69. Tebbenkamp AT, Green C, Xu G, Denovan-Wright EM, Rising AC, et al. 2011. Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative. Hum. Mol. Genet. 20:2770-82
70. Waldron-Roby E, Ratovitski T, Wang X, Jiang M, Watkin E, et al. 2012. Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin. J. Neurosci. 32:183-93
71. Warby SC, Doty CN, Graham RK, Shively J, Singaraja RR, Hayden MR. 2009. Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol. Cell. Neurosci. 40:121-27
72. Preisinger E, Jordan BM, Kazantsev A, Housman D. 1999. Evidence for a recruitment and sequestration mechanism in Huntingtons disease. Philos. Trans. R. Soc. Lond. B 354:1029-34
73. Tanzi RE, Bertram L. 2005. Twenty years of the Alzheimers disease amyloid hypothesis: A genetic perspective. Cell 120:545-55
74. Goedert M, Spillantini MG. 2006. A century of Alzheimers disease. Science 314:777-81
75. Scheff SW, Price DA. 2003. Synaptic pathology in Alzheimers disease: A review of ultrastructural studies. Neurobiol. Aging 24:1029-46
76. Mattson MP. 2004. Pathways towards and away from Alzheimers disease. Nature 430:631-39
77. LeBlanc AC. 2005. The role of apoptotic pathways in Alzheimers disease neurodegeneration and cell death. Curr. Alzheimer Res. 2:389-402
78. Sheng M, Sabatini BL, Sudhof TC. 2012. Synapses and Alzheimers disease. Cold Spring Harb. Perspect. Biol. 4:a005777
79. Mudher A, Lovestone S. 2002. Alzheimers disease-do tauists and baptists finally shake hands? Trends Neurosci. 25:22-26
80. LeBlanc AC. 2013. Caspase-6 as a novel early target in the treatment of Alzheimers disease. Eur. J. Neurosci. 37:2005-18
81. Kitamura Y, Shimohama S, Kamoshima W, Matsuoka Y, Nomura Y, Taniguchi T. 1997. Changes of p53 in the brains of patients with Alzheimers disease. Biochem. Biophys. Res. Commun. 232:418-21
82. MacLachlan TK, El-Deiry WS. 2002. Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc. Natl. Acad. Sci. USA 99:9492-97
83. Pompl PN, Yemul S, Xiang Z, Ho L, Haroutunian V, et al. 2003. Caspase gene expression in the brain as a function of the clinical progression of Alzheimer disease. Arch. Neurol. 60:369-76
84. Ramcharitar J, Albrecht S, Afonso VM, Kaushal V, Bennett DA, LeBlanc AC. 2013. Cerebrospinal fluid tau cleaved by caspase-6 reflects brain levels and cognition in aging and Alzheimer disease. J. Neuropathol. Exp. Neurol. 72:824-32
85. Albrecht S, Bogdanovic N, Ghetti B, Winblad B, LeBlanc AC. 2009. Caspase-6 activation in familial Alzheimer disease brains carrying amyloid precursor protein or presenilin I or presenilin II mutations. J. Neuropathol. Exp. Neurol. 68:1282-93
86. Klaiman G, Petzke TL, Hammond J, LeBlanc AC. 2008. Targets of caspase-6 activity in human neurons and Alzheimer disease. Mol. Cell. Proteomics 7:1541-55
87. Adrain C, Murphy BM, Martin SJ. 2005. Molecular ordering of the caspase activation cascade initiated by the cytotoxic T lymphocyte/natural killer (CTL/NK) protease granzyme B. J. Biol. Chem. 280:4663-73
88. Harigaya Y, Shoji M, Shirao T, Hirai S. 1996. Disappearance of actin-binding protein, drebrin, from hippocampal synapses in Alzheimers disease. J. Neurosci. Res. 43:87-92
89. Halawani D, Tessier S, Anzellotti D, Bennett DA, Latterich M, LeBlanc AC. 2010. Identification of Caspase-6-mediated processing of the valosin containing protein (p97) in Alzheimers disease: A novel link to dysfunction in ubiquitin proteasome system-mediated protein degradation. J. Neurosci. 30:6132-42
90. Gralle M, Ferreira ST. 2007. Structure and functions of the human amyloid precursor protein: the whole is more than the sum of its parts. Prog. Neurobiol. 82:11-32
91. Bredesen DE. 2009. Neurodegeneration in Alzheimers disease: caspases and synaptic element interdependence. Mol. Neurodegener. 4:27
92. Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, et al. 1997. A combinatorial approach defines specificities ofmembers of the caspase family and granzyme B: functional relationships established for key mediators of apoptosis. J. Biol. Chem. 272:17907-11
93. Pellegrini L, Passer BJ, Tabaton M, Ganjei JK, DAdamio L. 1999. Alternative, non-secretase processing of Alzheimers β-amyloid precursor protein during apoptosis by caspase-6 and -8. J. Biol. Chem. 274:21011-16
94. Bredesen DE, John V, Galvan V. 2010. Importance of the caspase cleavage site in amyloid-β protein precursor. J. Alzheimers Dis. 22:57-63
95. Banwait S, Galvan V, Zhang J, Gorostiza OF, Ataie M, et al. 2008. C-terminal cleavage of the amyloid-β protein precursor at Asp664: A switch associated with Alzheimers disease. J. Alzheimers Dis. 13:1-16
96. Hell K, Saleh M, Crescenzo GD, OConnor-McCourt MD, Nicholson DW. 2003. Substrate cleavage by caspases generates protein fragments with Smac/Diablo-like activities. Cell Death Differ. 10:1234-39
97. Park SA, Shaked GM, Bredesen DE, Koo EH. 2009. Mechanism of cytotoxicity mediated by the C31 fragment of the amyloid precursor protein. Biochem. Biophys. Res. Commun. 388:450-55
98. Galvan V, Zhang J, Gorostiza OF, Banwait S, Huang W, et al. 2008. Long-term prevention of Alzheimers disease-like behavioral deficits in PDAPPmice carrying a mutation in Asp664. Behav. Brain Res. 191:246-55
99. Zhang J, Gorostiza OF, Tang H, Bredesen DE, Galvan V. 2010. Reversal of learning deficits in hAPP transgenic mice carrying a mutation at Asp664: A role for early experience. Behav. Brain Res. 206:202-7
100. Rohn TT, Kokoulina P, Eaton CR, Poon WW. 2009. Caspase activation in transgenic mice with Alzheimer-like pathology: results from a pilot study utilizing the caspase inhibitor, Q-VD-OPh. Int. J. Clin. Exp. Med. 2:300-8
101. McPhie DL, Coopersmith R, Hines-Peralta A, Chen Y, Ivins KJ, et al. 2003. DNAsynthesis and neuronal apoptosis caused by familial Alzheimer disease mutants of the amyloid precursor protein are mediated by the p21 activated kinase PAK3. J. Neurosci. 23:6914-27
102. Zhao L, Ma QL, Calon F, Harris-White ME, Yang F, et al. 2006. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat. Neurosci. 9:234-42
103. Salvesen GS, Duckett CS. 2002. IAP proteins: blocking the road to deaths door. Nat. Rev. Mol. Cell Biol. 3:401-10
104. Van de Craen M, Declercq W, Van den brande I, Fiers W, Vandenabeele P. 1999. The proteolytic procaspase activation network: an in vitro analysis. Cell Death Differ. 6:1117-24
105. Cowling V, Downward J. 2002. Caspase-6 is the direct activator of caspase-8 in the cytochrome c- induced apoptosis pathway: absolute requirement for removal of caspase-6 prodomain. Cell Death Differ. 9:1046-56
106. Chai J, Wu Q, Shiozaki E, Srinivasula SM, Alnemri ES, Shi Y. 2001. Crystal structure of a procaspase-7 zymogen: mechanisms of activation and substrate binding. Cell 107:399-407
107. Stanger K, Steffek M, Zhou L, Pozniak CD, Quan C, et al. 2012. Allosteric peptides bind a caspase zymogen and mediate caspase tetramerization. Nat. Chem. Biol. 8:655-60
108. Suzuki A, Kusakai G, Kishimoto A, Shimojo Y, Miyamoto S, et al. 2004. Regulation of caspase-6 and FLIP by the AMPK family member ARK5. Oncogene 23:7067-75
109. Suzuki A, Lu J, Kusakai G, Kishimoto A, Ogura T, Esumi H. 2004. ARK5 is a tumor invasion-associated factor downstream of Akt signaling. Mol. Cell. Biol. 24:3526-35
110. Humbert S, Bryson EA, Cordelieres FP, Connors NC, Datta SR, et al. 2002. The IGF-1/Akt pathway is neuroprotective in Huntingtons disease and involves Huntingtin phosphorylation by Akt. Dev. Cell 2:831-37
111. Warby SC, Chan EY, Metzler M, Gan L, Singaraja RR, et al. 2005. Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Hum. Mol. Genet. 14:1569-77
112. Baumgartner R, Meder G, Briand C, Decock A, DArcy A, et al. 2009. The crystal structure of caspase-6, a selective effector of axonal degeneration. Biochem. J. 423:429-39
113. Heise CE, Murray J, Augustyn KE, Bravo B, Chugha P, et al. 2012. Mechanistic and structural understanding of uncompetitive inhibitors of caspase-6. PLoS ONE 7:e50864
114. Muller I, Lamers MB, Ritchie AJ, Dominguez C, Munoz-Sanjuan I, Kiselyov A. 2011. Structure of human caspase-6 in complex with Z-VAD-FMK: new peptide binding mode observed for the non-canonical caspase conformation. Bioorg. Med. Chem. Lett. 21:5244-47
115. Muller I, Lamers MB, Ritchie AJ, Park H, Dominguez C, et al. 2011. A new apo-caspase-6 crystal form reveals the active conformation of the apoenzyme. J. Mol. Biol. 410:307-15
116. Vaidya S, Velazquez-Delgado EM, Abbruzzese G, Hardy JA. 2011. Substrate-induced conformational changes occur in all cleaved forms of caspase-6. J. Mol. Biol. 406:75-91
117. Xu G, Cirilli M, Huang Y, Rich RL, Myszka DG, Wu H. 2001. Covalent inhibition revealed by the crystal structure of the caspase-8/p35 complex. Nature 410:494-97
118. Lee AW, Champagne N, Wang X, Su XD, Goodyer C, LeBlanc AC. 2010. Alternatively spliced caspase- 6B isoform inhibits the activation of caspase-6A. J. Biol. Chem. 285:31974-84
119. Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thornberry NA. 1998. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J. Biol. Chem. 273:32608-13
120. Erlanson DA, Wells JA, Braisted AC. 2004. Tethering: fragment-based drug discovery. Annu. Rev. Biophys. Biomol. Struct. 33:199-223
121. James KE, Asgian JL, Li ZZ, Ekici OD, Rubin JR, et al. 2004. Design, synthesis, and evaluation of azapeptide epoxides as selective and potent inhibitors of caspases-1, -3, -6, and -8. J. Med. Chem. 47:1553-74
122. Nedev HN, Klaiman G, LeBlanc A, Saragovi HU. 2005. Synthesis and evaluation of novel dipeptidyl benzoyloxymethyl ketones as caspase inhibitors. Biochem. Biophys. Res. Commun. 336:397-400
123. Ekici OD, Li ZZ, Campbell AJ, James KE, Asgian JL, et al. 2006. Design, synthesis, and evaluation of aza-peptide Michael acceptors as selective and potent inhibitors of caspases-2, -3, -6, -7, -8, -9, and -10. J. Med. Chem. 49:5728-49
124. Henzing AJ, Dodson H, Reid JM, Kaufmann SH, Baxter RL, Earnshaw WC. 2006. Synthesis of novel caspase inhibitors for characterization of the active caspase proteome in vitro and in vivo. J. Med. Chem. 49:7636-45
125. McStay GP, Salvesen GS, Green DR. 2008. Overlapping cleavage motif selectivity of caspases: implications for analysis of apoptotic pathways. Cell Death Differ. 15:322-31
126. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:3-26
127. Chu W, Rothfuss J, Chu Y, Zhou D, Mach RH. 2009. Synthesis and in vitro evaluation of sulfonamide isatin Michael acceptors as small molecule inhibitors of caspase-6. J. Med. Chem. 52:2188-91
128. Murray J, Renslo AR. 2013. Modulating caspase activity: beyond the active site. Curr. Opin. Struct. Biol. 23:812-19
129. Murray J, Giannetti AM, Steffek M, Gibbons P, Hearn BR, et al. 2014. Tailoring small molecules for an allosteric site on procaspase-6. ChemMedChem 9(1):73-77
130. Velazquez-Delgado EM, Hardy JA. 2012. Zinc-mediated allosteric inhibition of caspase-6. J. Biol. Chem. 287:36000-11
131. Huber KL, Hardy JA. 2012. Mechanism of zinc-mediated inhibition of caspase-9. Protein Sci. 21:1056-65
132. Hou X, Liu JE, Liu W, Liu CY, Liu ZY, Sun ZY. 2011. A new role of NUAK1: directly phosphorylating p53 and regulating cell proliferation. Oncogene 30:2933-42
133. Pehlivan SB. 2013. Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharm. Res. 30:2499-511